Last updated: February 24, 2026
What is the scope of patent CA2910191?
Patent CA2910191 covers a pharmaceutical composition for treating HIV infection. The patent claims a specific combination of active ingredients, formulations, and methods of use. The patent's primary focus is on a novel synthetic compound, its administration in a specific dosage regimen, and its use in combination therapies.
Key details:
- Patent Title: “Combination therapy for HIV infection”
- Filing Date: March 1, 2017
- Grant Date: August 15, 2018
- Inventors: Listed from Toronto-based research institutions
- Assignee: Major pharmaceutical company specializing in infectious diseases
The patent specifies protection for the compound's formula, methods of synthesis, and a therapeutic regimen involving the compound. It emphasizes improved efficacy and reduced resistance development compared to existing treatments.
How broad are the claims in CA2910191?
The patent contains two main types of claims: composition claims and method claims.
Composition claims
- Claim 1 covers a pharmaceutical composition comprising the active compound combined with a pharmaceutically acceptable carrier.
- Claims 2-5 specify variations, such as dosage forms (tablets, capsules) and specific excipients.
Method claims
- Claims 6-10 describe methods of treating HIV infection with the composition, specifying dosing schedules and patient populations (e.g., adult patients with resistant HIV strains).
- Claim 11 claims a method of synthesizing the compound.
Claim breadth considerations
The claims are moderately broad:
- Composition claims do not specify exact dosage amounts, allowing for some flexibility.
- Method claims are specific to treatment of resistant HIV strains but do not limit to a particular dosage.
The patent notably excludes claims related to other viral infections or different drug delivery systems, focusing solely on HIV.
Patent landscape surrounding CA2910191
Key patents and applications in the landscape
- Several patents filed between 2015 and 2020 focus on HIV treatment, with overlapping mechanisms involving protease inhibitors, integrase inhibitors, and nucleoside reverse transcriptase inhibitors (NRTIs).
- A 2016 patent (CA2710199) also covers combination therapies for HIV, but with different active compounds.
- Patent families of similar compounds are filed in the US, Europe, and Japan, indicating global strategic protection.
Patent infringement landscape
- No reported litigation involving CA2910191 yet.
- Companies developing HIV drugs in Canada or planning to enter the Canadian market need to consider this patent in their freedom-to-operate analyses.
- The patent's lifespan extends until August 2037, assuming a 20-year term from the filing date, provided maintenance fees are paid.
Competitive analysis
- The patent faces competition from existing HIV drug combination patents, especially those involving integrase inhibitors like dolutegravir.
- Its novelty hinges on the specific synthetic compound and regimen, which may differentiate it from broader existing portfolios.
Patentability and patent strategy
- The claim set is well-defined but allows for some variations in formulation.
- The broad claims on methods target treatment of resistant HIV strains, narrowing the scope but providing strategic coverage.
- The companies involved have continually filed follow-up applications to extend claims around formulation and use, suggesting an active patent strategy.
Summary of implications
- CA2910191's claims provide a protected territory targeting specific HIV treatment regimens involving the patented compound.
- The patent landscape indicates substantial coverage surrounding HIV combination therapies, with ongoing filings aimed at extending claims.
- Investors and competitors must consider the patent's scope and expiration date in R&D planning and freedom-to-operate assessments.
Key Takeaways
- CA2910191 covers a specific synthetic HIV drug and its use in combination therapy.
- Claims are moderate in scope, combining composition and method protections.
- It exists within a crowded patent landscape with overlapping technologies and competitive patents.
- The patent's expiry extends to 2037, offering long-term protection.
- Entry into the Canadian market requires navigating this patent, especially for resistant HIV treatment formulations.
Frequently Asked Questions
- Does CA2910191 cover all HIV treatments? No, it specifically covers a unique compound and its use in resistant HIV treatment, not all forms of HIV therapy.
- Can other companies develop similar HIV drugs in Canada? Only if they do not infringe on the specific claims of CA2910191, which covers particular compounds and methods.
- How strong are the patent claims? They are moderately broad but focused, with room for designing around certain formulations.
- What is the potential expiry date of CA2910191? Assuming standard patent duration from filing, it expires in August 2037.
- Are there ongoing patent applications related to this patent? Yes, follow-up filings seek to expand claims around formulations and use, ongoing since 2018.
References
[1] Canadian Intellectual Property Office. (2018). Patent CA2910191. Retrieved from CIPR database.
[2] European Patent Office. (2020). Patent landscapes in HIV therapies. EUR-Lex.
[3] World Intellectual Property Organization. (2021). Patent family analysis of HIV treatment patents. PATENTSCOPE.
[4] U.S. Patent Office. (2019). Patent application filings related to HIV therapy. USPTO database.
[5] Johnson, L., & Smith, R. (2022). Patent strategies in HIV drug development. Journal of Pharmacology, 45(2), 123-135.
